Beam Therapeutics Inc.
BEAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745999
In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 277 institutions reported holding it in 13F filings for Q2 2026, worth $3.75B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Holders of 5% or more of BEAM
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Beam Therapeutics Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 12.60%12.8M shares | −1.00 ppfrom 13.60% | Feb 12, 20255 filings | Feb 5, 2026 | SEC |
| ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 12.29%12.5M shares | +1.94 ppfrom 10.35% | Jan 10, 20253 filings | Feb 3, 2026 | SEC |
| Farallon Capital Partners, L.P. | 13G/A | 9.99%10.1M shares | 0.00 ppfrom 9.99% | Feb 5, 20253 filings | Feb 5, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.50%7.50M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| State Street Corp | 13G | 5.20%5.23M shares | New | Feb 9, 20261 filing | Feb 9, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
16 Schedule 13D and 13G filings on Beam Therapeutics Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20264:11 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 9, 20266:19 AM ET | State Street Corp | 13G | 5.20%5.23M shares | New | Dec 31, 2025 | SEC |
| Feb 5, 20262:56 PM ET | Farallon Capital Partners, L.P.and 30 others | 13G/A | 9.99%10.1M shares | 0.00 ppfrom 9.99% | Dec 31, 2025 | SEC |
| Feb 5, 20261:16 PM ET | FMR LLCand 1 other | 13G/A | 12.60%12.8M shares | −1.00 ppfrom 13.60% | Dec 31, 2025 | SEC |
| Feb 3, 202611:34 AM ET | ARK Investment Management LLCand 1 otherSuperinvestorARK Invest | 13G/A | 12.29%12.5M shares | +1.94 ppfrom 10.35% | Dec 31, 2025 | SEC |
| Nov 5, 202511:26 AM ET | FMR LLCand 1 other | 13G/A | 13.60%13.8M shares | −1.40 ppfrom 15.00% | Sep 30, 2025 | SEC |
| Aug 7, 202511:35 AM ET | ARK Investment Management LLCand 1 otherSuperinvestorARK Invest | 13G/A | 10.35%10.4M shares | +2.43 ppfrom 7.92% | Jul 31, 2025 | SEC |
| Aug 6, 202511:51 AM ET | FMR LLCand 1 other | 13G/A | 15.00%15.1M shares | +4.90 ppfrom 10.10% | Jun 30, 2025 | SEC |
| May 15, 20255:04 PM ET | ARCH Venture Fund IX, L.P.and 7 others | 13G/A | 4.60%4.60M shares | −1.00 ppfrom 5.60%Below 5% | Mar 31, 2025 | SEC |
| May 13, 20253:45 PM ET | Farallon Capital Partners, L.P.and 29 others | 13G/A | 9.99%9.97M shares | +0.09 ppfrom 9.90% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.50%7.50M shares | – | Mar 31, 2025 | SEC |
| Apr 2, 202511:02 AM ET | FMR LLCand 1 other | 13G/A | 10.10%10.0M shares | +3.50 ppfrom 6.60% | Mar 31, 2025 | SEC |
| Feb 14, 20254:55 PM ET | ARCH Venture Fund IX, L.P.and 7 others | 13G/A | 5.60%4.60M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20259:16 AM ET | FMR LLCand 1 other | 13G/A | 6.60%5.44M shares | – | Dec 31, 2024 | SEC |
| Feb 5, 20257:30 PM ET | Farallon Capital Partners, L.P.and 29 others | 13G/A | 9.90%8.24M shares | – | Dec 31, 2024 | SEC |
| Jan 10, 20259:46 PM ET | ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 7.92%6.53M shares | – | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Beam Therapeutics Inc. shares.
No Form 144 notices for Beam Therapeutics Inc. are on file.